Trial Profile
A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 polysaccharide (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 May 2009 New trial record